Potential Influences of the COVID-19 Pandemic on Drug Use and HIV Care Among People Living with HIV and Substance Use Disorders: Experience from a Pilot mHealth Intervention

[1]  Carlos Del Rio,et al.  Mild or Moderate Covid-19. , 2020, The New England journal of medicine.

[2]  D. Cucinotta,et al.  WHO Declares COVID-19 a Pandemic , 2020, Acta bio-medica : Atenei Parmensis.

[3]  T. Burki.  Coronavirus in China , 2020, The Lancet Respiratory Medicine.

[4]  Dhavan V. Shah,et al.  A Mobile Health Intervention to Improve Hepatitis C Outcomes Among People With Opioid Use Disorder: Protocol for a Randomized Controlled Trial , 2019, JMIR research protocols.

[5]  Dhavan V. Shah,et al.  The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial , 2016, Trials.

[6]  A. Westfall,et al.  The Contribution of Missed Clinic Visits to Disparities in HIV Viral Load Outcomes. , 2015, American journal of public health.

[7]  Seyed Mojtaba Yassini Ardekani,et al.  Emotional and Social Loneliness in Individuals With and Without Substance Dependence Disorder , 2014, International journal of high risk behaviors & addiction.

[8]  M. Mugavero,et al.  Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States. , 2013, AIDS patient care and STDs.

[9]  Jennifer A. Pellowski,et al.  A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. , 2013, The American psychologist.

[10]  K. Robertson,et al.  Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362 , 2011, AIDS care.

[11]  D. Rumball,et al.  Substance Use and Mental Health , 2008 .

[12]  S. Safren,et al.  Behavioral aspects of HIV care: adherence, depression, substance use, and HIV-transmission behaviors. , 2007, Infectious disease clinics of North America.

[13]  Lehida Meléndez-Morales,et al.  Health Disparities in HIV / AIDS , Viral Hepatitis , Sexually Transmitted Diseases , and Tuberculosis in the United States , 2007 .

[14]  David R Bangsberg,et al.  Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  D. Descamps,et al.  Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  B. Yip,et al.  Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up , 2002, AIDS.

[17]  Marilyn M. Wagener,et al.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection (vol 133, pg 21, 2000) , 2002 .

[18]  A. Zolopa,et al.  Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. , 2001, AIDS.

[19]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[20]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[21]  H. Haverkos.  Infectious diseases and drug abuse. Prevention and treatment in the drug abuse treatment system. , 1991, Journal of substance abuse treatment.

[22]  B. Leigh.  Alcohol and unsafe sex: an overview of research and theory. , 1990, Progress in clinical and biological research.

[23]  R. Stall.  The prevention of HIV infection associated with drug and alcohol use during sexual activity. , 1988, Advances in alcohol & substance abuse.